Surrogate end points in heart failure  by Anand, Inder S et al.
REVIEW ARTICLES
Surrogate End Points in Heart Failure
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Minneapolis, Minnesota and Seattle, Washington
Because of the increasing number of pharmacologic strategies available for treatment of heart
failure (HF), the time has come to reassess the adequacy of end points used to evaluate
therapeutic efficacy. Interest in the use of surrogate end points in clinical studies is increasing.
A surrogate end point is defined as a measurement that can substitute for a true end point for
the purpose of comparing specific interventions or treatments in a clinical trial. A true end
point is one that is of clinical importance to the patient (e.g., mortality or quality of life),
whereas a surrogate end point is one biologically closer to the disease process (e.g., ejection
fraction or left ventricular volume in HF). The prime motivation for the use of a surrogate end
point concerns the possible reduction in sample size or trial duration. Such reductions have
important cost implications and in some cases may influence trial feasibility. Another, perhaps
more important, aspect of measuring surrogate end points is that they increase our
understanding of the mechanism of action of drugs and thus may help physicians to take a
more enlightened approach in managing their patients. In this article we have analyzed the
possible potentials of the surrogate end points in clinical studies of patients with chronic HF.
Other uses of possible surrogates are discussed, and the limitations in finding true surrogates
are mentioned. At this time we conclude there is no well established surrogate in HF. (J Am
Coll Cardiol 2002;39:1414–21) © 2002 by the American College of Cardiology Foundation
Chronic heart failure (HF) affects 2% of the population and
is the fourth leading cause of adult hospitalizations in the
U.S. and the most frequent cause of hospitalization in
patients older than 65 years (1,2). The primary objectives in
the treatment of patients with HF are to improve quality of
life (QOL) and increase survival. Because the number of
pharmacologic agents used in the treatment of HF is
increasing and the mortality decreasing, the time has come
to reassess the adequacy of end points used to evaluate
therapeutic efficacy. Reduction in mortality is regarded as
the gold standard. However, the large sample size that may
be required to show an incremental survival advantage of a
new drug is relatively prohibitive. Therefore, there has been
recent increased interest in the use of surrogate end points,
variables that can substitute for true end points for the
purpose of comparing specific interventions in a clinical
trial.
Surrogate end points have several potential advantages.
Clinical trials evaluating surrogate end points require
smaller sample size and can sometimes be completed in
months rather than years. The ability to bring effective
therapies to clinical practice quickly and inexpensively
makes surrogate end points attractive in the drug-approval
process. The principal disadvantage of using surrogates to
assess therapies is the possibility of an incomplete, inade-
quate, or misleading evaluation (3–5). Drugs usually have
multiple effects, and resorting to a single surrogate end
point, focused exclusively on one intermediate effect, often
precludes the evaluation of other intended or unintended
health effects. Although even large clinical trials may not
provide a complete evaluation of safety for rare adverse
events, the relatively small sample size and the short
duration typical in surrogate end-point trials provide little
assurance of long-term safety. To use only surrogate end
points is therefore to accept as empirical evidence for clinical
practice a hypothesis about health benefits that has never
been directly tested. The aim of this article was to analyze
the possible potential of suggested surrogate end points for
clinical studies of patients with chronic HF.
Most of the discussion of the use of surrogates has been
in a very strong sense of the word “surrogate.” For example,
for a number of years the U.S. Food and Drug Adminis-
tration (FDA) has approved medications that lower blood
pressure with a presumed acceptable benefit/risk ratio. The
presumption has been that any compound that lowers blood
pressure in a hypertensive population would convey the
benefits of preventing selected cardiovascular events as
shown in early long-term placebo-controlled trials. The
benefit is assumed even though the underlying biological
mechanism of lowering blood pressure may differ. This
would be one type of surrogate: a strong surrogate. For a
well-defined end point or end points, appropriate changes in
the surrogate are regarded as establishing appropriate
changes in the end point(s).
There may be other potential variables not accepted as
definitely establishing benefit for an end point(s) but con-
sidered so close that it is rational to use the putative
surrogate variable for drug development in all but the final
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phase III trials of a new compound. Such variables might be
used for dose ranging, preliminary proof of efficacy (phase I
and II evaluation) and initial examination of the benefit/risk
ratio. Such a variable might serve as a developmental surro-
gate, a measurement considered closely related to an end
point of clinical benefit that makes it appropriate to use the
developmental surrogate for dose ranging and preliminary
proof of efficacy and benefit/risk ratio. Use of a develop-
mental surrogate could result in considerable savings in time
and resources, albeit with some risk for the final evaluation
if the surrogate is not appropriate.
There has been much discussion about when engaging in
only one trial is adequate for regulatory approval. In addi-
tion to evidence obtained with formal hypothesis testing
and the associated p value, other evidence can be brought to
support the findings. Variables known to be closely associ-
ated and predictive of a beneficial outcome can be used to
support and strengthen the controlled trial data. This would
be a supportive surrogate, a variable that strengthens the
plausibility of favorable results from other controlled data.
TRUE END POINTS IN HF TRIALS
Because HF is a life-threatening and debilitating disorder,
the true end points in HF should reflect patients’ symptoms
as well as their quality and duration of life.
Survival as a true end point. Mortality is currently re-
garded as the most important end point for evaluation of
new HF drugs, and a reduction in mortality, or alternatively
another beneficial effect with assurance of no important
increase in mortality, is important for regulatory approval of
the drug. Although mortality is a strong and easily measured
end point, it has several limitations. The main concern of
using only mortality as an end point is that it refers to the
extreme manifestation of HF. Thus, most of the patients in
the study do not contribute to a mortality primary end
point, yet have important QOL issues. Because the current
management of HF with angiotensin-converting enzyme
(ACE) inhibitors and beta-blockers has reduced the event
rate considerably, if mortality is the primary end point,
patients with advanced diseases have to be studied to get
enough events for reasonable statistical power in a reason-
able period of time.
Consequently, patients in early stages of HF, in whom
the disease process is most likely to be halted or possibly
reversed, are not evaluated. Preventive strategy is therefore
not assessed. Finally, trials using mortality as the primary
end point require a large sample size to show a survival
advantage of a new drug.
Symptoms and quality-of-life questionnaires. The most
direct approach to the evaluation of HF is to inquire about
symptoms, although to date this has not been an important
aspect of HF regulatory discussions. Quality-of-life (QOL)
questionnaires, which provide comprehensive information
about the effects of a disease and its treatment on patients’
lives, are now widely used in clinical trials. The QOL
questionnaires can be general or disease-specific, and there
is no general agreement as to which type of questionnaire is
most appropriate. Few questionnaires have been validated in
HF patients in a way that shows that the results correlate
with the severity of disease.
Many ongoing studies of treatments for chronic HF
incorporate the Minnesota Living with Heart Failure ques-
tionnaire as a measure of QOL (6). Statistically significant
improvements in the QOL score have been observed in
placebo-controlled studies of enalapril, flosequinan, pimo-
bendan, vesnarinone and valsartan (7–11). However, flose-
quinan, pimobendan and vesnarinone have also been shown
to have an adverse effect on survival (10,12,13), raising the
issue of a trade-off between improved QOL and the risk of
drug-induced death. Increased mortality with these and
other agents clearly indicates that symptomatic benefit in
HF does not necessarily predict improved survival (14).
Because it is generally believed that a pharmacologic agent
that improves symptoms in HF should have at least a
relatively neutral survival effect, the pharmacologic industry
has never pursued an HF indication for any of the above
mentioned agents. The important issue of a trade-off
between QOL and mortality has been discussed extensively
by Patrick and Erickson (15).
SURROGATE END POINTS IN HF TRIALS
Chronic HF is the final common end point of several
processes involved in the cardiovascular continuum that are
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initiated by risk factors for cardiovascular diseases. Once
initiated, cardiovascular disease progresses through struc-
tural remodeling of the heart and blood vessels. Factors that
contribute to this include activation of various neurohor-
mones, growth factors and cytokines. Markers of this
biological process (e.g., left ventricular [LV] hypertrophy
and enlargement) and factors that contribute to it (e.g.,
neurohormones) may be viewed as surrogates of the pro-
gression of the disease.
DEFINITION AND
REQUIREMENTS FOR A SURROGATE END POINT
Several definitions have been suggested for a surrogate end
point (16,17). For a surrogate end point to be considered an
adequate substitute for the real end point, several levels of
evidence must be provided (16,18–20). First, the biological
relevance of the postulated relationship needs to be estab-
lished by showing a strong and consistent relationship
between the candidate for surrogate status (e.g., LV volume
in HF patients) and outcomes in numerous studies of
different populations and disease states (16). Second,
changes in the surrogate end point (e.g., plasma brain
natriuretic peptide [BNP] level) should predict a change in
the morbid event independent of treatment. Third, a
consistent proportionality between the degree of change in
the surrogate end point and the true end point needs to be
documented in a spectrum of studies, so that the magnitude
of change in the surrogate end point can be used to predict
the actual change in the true end point (e.g., change in LV
volume and survival). Finally, this association needs to be
replicated in a variety of different populations, in both
observational studies and treatment trials, using a spectrum
of therapeutic interventions. Although insistence on strict
mathematical proof of these four criteria may make it
impossible to validate any surrogate end point fully, they
provide a set of useful benchmarks in assessing the practi-
cality of using surrogate end points.
A more realistic expectation is that the surrogate end
point accounts for a substantial portion of the treatment
effect on the true clinical end point. A physiologic variable
can be proposed as a surrogate end point when the variable
meets two basic criteria (3). First, a statistical relationship
must exist between the change in the proposed surrogate
end point over time and the clinical outcome. Second, a
pathophysiologic basis must exist for believing that the
change in the surrogate end point is the primary determi-
nant of the outcome.
Thus, surrogate end points in HF patients should un-
equivocally reflect the true end points (i.e., survival and the
QOL). More than 150 clinical, hemodynamic, or exercise
variables have been identified as predictors of survival in
patients with HF. Some have been tested in clinical trials,
but not completely validated. We will focus on hemody-
namic measurements, ventricular arrhythmias, autonomic
nervous system markers, exercise capacity, neurohormones
and variables of LV structure and function as potential
surrogate end points for patients with chronic HF.
Hemodynamic measurements. During the 1980s, HF was
considered primarily a hemodynamic disorder, and physi-
cians believed that therapeutic interventions that improved
pump function would predictably benefit patients. Invasive
hemodynamic studies to assess cardiac output and right
ventricular (RV) and LV filling pressures were viewed as
crucial in development programs for new drugs. Later
studies, however, have raised important concerns about the
validity of acute hemodynamic changes as surrogate end
points. A number of controlled clinical trials conducted in
the 1990s (9,10,13,21–23) have shown that drugs that
produce striking hemodynamic benefits do not necessarily
produce long-term clinical benefits. These findings have
discouraged the use of hemodynamic variables as surrogate
markers for drug efficacy. However, the converse is not true.
All the drugs approved for treatment of HF have long-term
beneficial hemodynamic effects, and there are no drugs that
worsen hemodynamics and improve long-term outcomes.
Hemodynamic variables are still viewed as the main vari-
ables for assessing the efficacy of intravenous (IV) drugs for
the treatment of acute HF (3).
Ventricular arrhythmias. Ventricular premature depolar-
izations, a risk factor for sudden and non-sudden cardiac
death after myocardial infarction (MI) (24), have been
associated with a lower ejection fraction (EF) and larger
heart size in patients with chronic HF (25). Drugs that
suppress ventricular premature beats were therefore ex-
pected to prolong life (26). Several clinical trials, however,
have failed to show that drugs that reduce the frequency and
complexity of disturbances in rhythm decrease the long-
term risk of sudden death (27). These results demonstrate
that ventricular premature beats cannot be considered valid
surrogate markers, though they are clearly an important risk
factor.
Autonomic nervous system markers. Recent compelling
evidence linking the autonomic nervous system and cardiac
mortality, including sudden death (28–31), suggests that
parameters such as heart rate variability, baroreceptor sen-
sitivity and ventricular repolarization characteristics (QT
dispersion) may well serve as potential surrogate markers.
Yee and Struthers (32) analyzed the impact of drugs on
mortality and autonomic nervous system surrogate markers
and found heart rate variability and QT dispersion to be the
most promising surrogates for sudden death in HF. Never-
theless, the predictive value of many of the autonomic
markers is at present uncertain. It is important to reiterate
that a strong predictive marker may not result in the
expected-as-modeled change in outcome when using a drug
that also changes the predictor.
Exercise capacity. Traditionally, functional capacity in HF
is classified according to a categoric scale, such as that of the
New York Heart Association (NYHA), and the efficacy of
a therapeutic intervention is judged using each patient as his
or her own control. Although it is simple, such a classifica-
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tion is not quantifiable, is subject to considerable interob-
server variability and lacks adequate sensitivity to detect
important changes in functional capacity. Given these
difficulties, various quantitative and objective measurements
of functional capacity have been developed in recent years.
The 6-min walk test (33) was found to predict long-term
mortality and HF hospitalization rates in patients with LV
dysfunction of varying cause and severity (34,35). The test
can be administered safely in an outpatient setting without
specialized equipment and is well accepted by patients.
However, the test is subjective, and its usefulness in serially
monitoring therapy and progression of LV dysfunction has
not been fully explored. Some recent data have not con-
firmed the predictive value of the distance walked on
survival (36), especially in patients with mild HF and
preserved exercise tolerance (37). The 6-min walk distance
is therefore considered helpful in clinical descriptions of HF
patients but cannot be used as a surrogate marker for
assessing the survival prognosis.
Treadmill or cycle exercise testing has generally shown that
therapeutic interventions that lessen symptoms in HF pa-
tients also improve exercise tolerance and, conversely, that
symptomatically ineffective drugs produce little change in
exercise capacity. Exercise tolerance, expressed as exercise
time or workload achieved on an ergometer, has been
recognized for several decades as an important prognostic
marker in patients with heart disease (38). In recent years,
there has been increased interest in directly measured
maximal oxygen uptake (peak VO2) during exercise. Peak
VO2 is considered the best criteria of exercise capacity in
patients with chronic HF (39–41). An objective measure of
maximal exertion, peak VO2 is used as an independent
prognostic indicator in HF (25,42) and in the selection of
patients for cardiac transplantation (43,44).
Some HF trials have shown that therapeutic interven-
tions that increase exercise capacity also improve survival
(45). However, an improvement in survival has not been
demonstrated with each therapeutic agent that improves
effort tolerance. Results from the Prospective Randomized
Milrinone Survival Evaluation (PROMISE) (21) and Ran-
domized Evaluation of FLosequinan on ExerCise Tolerance
(REFLECT) (46) trials have shown that early treatment-
induced improvements in exercise tolerance were unreliable
predictors of actual treatment effects on survival. In light of
the above, it might be useful to distinguish between the
short-term benefit on exercise capacity shown in PROM-
ISE (21) and REFLECT (46) trials and long-term effects
shown in the Vasodilator-Heart Failure Trial (V-HeFT)
studies (45).
Neurohormones. There is convincing evidence that neu-
rohormonal systems play major roles in the pathogenesis
and progression of HF (47). Two sets of neurohormones
with opposing effects are activated in the syndrome of HF.
The vasoconstrictor hormones are anti-natriuretic, antidi-
uretic and generally have growth-promoting properties,
whereas the vasodilator hormones are natriuretic, diuretic
and have anti-mitogenic effects. Norepinephrine (NE) and
the natriuretic peptides are the most studied neurohormones
in HF, and the strongest evidence for their pathogenetic
role comes from studies showing that modulation of these
neurohormones is associated with changes in clinical course
and survival.
Measurements of plasma NE were performed in the
Vasodilator-Heart Failure Trial II (V-HeFT II) to examine
the effects of therapy on neuroendocrine activation and the
responses to therapy among patients with different degrees
of activation. The baseline plasma NE data were grouped
into three relatively homogeneous strata: plasma NE 600
pg/ml, 600 to 900 pg/ml, and900 pg/ml (48). Cumulative
mortality was found to differ significantly between strata:
NE values600 pg/ml were associated with the lowest risk,
values between 600 and 900 pg/ml were associated with an
intermediate risk, and values900 pg/ml identified a group
at exceedingly high risk. The group treated with enalapril
had a significantly lower mortality than the group treated
with hydralazine-isosorbide dinitrate, and this benefit was
most evident in patients with NE values 900 pg/ml (48).
Similarly, in the Cooperative North Scandinavian Enalapril
Survival Study (CONSENSUS), significant reduction in
mortality seen with enalapril was confined to patients with
baseline NE levels above the median (49).
Other studies have raised important concerns about the
validity of plasma NE as a surrogate marker in HF treat-
ment trials. In the Australia–New Zealand Carvedilol Heart
Failure Trial, high baseline NE levels did not predict
additional survival benefit with carvedilol, which signifi-
cantly reduced HF admissions only in those patients with
NE levels below the median (50). The most worrisome
examples of disagreement between survival data and plasma
NE values come from studies with ibopamine (51,52) and
moxonidine (53). The PRIME II (Second Prospective
Randomized Study of Ibopamine on Mortality and Efficacy)
(52) and MOXCON (Effect of Sustained Release Mox-
onidine on Mortality and Morbidity in Patients with
Congestive Heart Failure) (53) trials were terminated pre-
maturely because of the adverse effects of ibopamine and
moxonidine on mortality despite significant reductions in
plasma NE. For the association of change in NE over time
and prognosis, a nonlinear effect was observed in the
recently completed BEST study (Beta-blocker Evaluation
of Survival Trial) (54). In this study, compared with the
intermediate or no-change group, those with a large de-
crease or a large increase in NE had a higher mortality (54).
Moreover, the largest decrease in NE was seen in the
African American population, who had a higher mortality.
These results limit the use of plasma NE as a surrogate
marker for HF trials.
Plasma natriuretic peptides are being recognized as im-
portant prognostic markers in patients with HF (49,55).
Brain natriuretic peptide (BNP), particularly its aminoter-
minal portion (N-BNP), appears to be one of the most
powerful neurohormonal predictors of LV function and
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prognosis in chronic HF (56–59). It has also emerged as an
important diagnostic marker (60,61). In the Australia–New
Zealand Carvedilol Heart Failure Trial, carvedilol reduced
mortality rates and HF admissions in those patients with
higher baseline BNP levels but lower plasma NE (50).
Moreover, N-BNP–guided treatment of HF was associated
with a significant reduction of total cardiovascular events,
including cardiovascular death and delay to first cardiovas-
cular event, compared with clinically guided treatment (62).
In a recent study on patients admitted with decompen-
sated HF, Cheng et al. (63) found that patients who had
good outcomes were characterized by decreases in both their
NYHA functional class and BNP levels during hospitaliza-
tion, whereas patients who were re-admitted within 30 days
of discharge had only minimal decreases in their BNP levels
during hospitalization, despite improvement in NYHA
classification. Finally, subjects who died in the hospital had
increasing BNP levels and little change in symptoms. These
data demonstrate a consistent relationship between the
BNP as a surrogate marker and outcomes (death and change
in symptom status). Changes in plasma BNP level were
associated with changes in the morbid events, suggesting
that plasma BNP may serve as a surrogate marker for HF
trials.
LV dimensions and ejection fraction. Baseline LV di-
mensions and ejection fraction (EF) have been shown to be
one of the most powerful predictors of survival after acute
MI (64–66), in chronic HF (25,67–69) and among people
free of overt cardiovascular disease (70–72). Many of the
beneficial effects of angiotensin-converting enzyme (ACE)
inhibitors and beta-blockers in HF appear to be related to
the ability of these agents to inhibit or to reverse cardiac
remodeling (73–78). In the Survival And Ventricular En-
largement (SAVE) trial, treatment with captopril was asso-
ciated with attenuation of LV enlargement over time and
improved clinical outcome (73,74). Serial assessments of LV
dimensions and function in the SOLVD, Australia–New
Zealand Carvedilol Heart Failure and CAPRICORN echo-
cardiographic substudies, and in the MERIT-HF magnetic
resonance imaging substudy, have also found an association
between favorable changes in LV dimensions and EF and
improved clinical outcome produced by enalapril, carvedilol
or metoprolol (75–78). Treatment with xamoterol was
shown to increase LV end-systolic and end-diastolic vol-
umes (79) and to increase mortality (80).
Cintron et al. (81) assessed the prognostic value of serial
changes in LVEF in patients with chronic HF and found a
significant and proportionate relationship between the di-
rection and magnitude of changes in EF over time and the
one-year mortality. Changes in LVEF 5% from baseline
at 6 months (V-HeFT I) and 12 months (V-HeFT II) were
the strongest predictors of mortality and remained signifi-
cant even after adjustment for therapy and baseline LVEF
(81). This is perhaps the only study that addressed and
found a consistent proportionality between the degree of
change in the surrogate end point and the subsequent
change in mortality. Thus, LV dimensions and their deriv-
ative EF seem to fulfill most of the criteria for surrogate end
points: baseline LV dimensions and EF are significantly
related to prognosis; changes in these measurements reflect
changes in mortality; and both the direction and the
magnitude of change in these variables cause a proportional
change in survival.
STATISTICAL APPROACH TO
TESTING THE VALIDITY OF USING A
SURROGATE END POINT FOR FUTURE HF TRIALS
The relatively easy part of evaluating potential surrogates in
HF trials is the evaluation of the predictive value for the end
point, usually survival or symptomatic status. For survival
modeling, the time to an end point is a well developed area
of statistics. For most purposes, proportional hazards sur-
vival models are adequate. However, when symptoms are
the object of investigation over an extended time period, the
expectation of many deaths is often a complicating factor.
An approach with much intuitive appeal is to consider time
when a patient is dead to be the “worst case,” and then to
take a time average (over the maximum possible exposure
time for a patient including the time after death as being in
the worst case status). In some cases, alternatively, the time
symptom-free may be used where time after death is
considered time with symptoms. It is more difficult to model
the effect of therapy for several reasons, for example: 1) most
surrogates will change with time, so that to model the effect
on survival a time-dependent approach will need to be
taken; 2) if the risk does not depend upon only the current
value, but also the history of the change, then a large
number of potential models may be used, and the potential
to very much over-fit the data is of concern; and 3) when a
surrogate is measured only occasionally and death represents
informative censoring the analysis is a very complex issue,
and much effort must be spent on sensitivity analyses to see
whether the purported effect holds up under scrutiny. At
this time, statistical theory is relatively weak in this area.
To examine the effect of change over time, both the
baseline and follow-up measurements would be used in the
model, and there should be statistical significance associated
with the follow-up measurement beyond any predictive
power of the baseline variable. If a semi-parametric model
(e.g., a proportional hazards or Cox model) or parametric
model holds, the model should imply an increasing treat-
ment effect as the surrogate change increases (at least over
most of the range of observed changes).
Conclusions. In the design of clinical trials, choice of the
most appropriate outcome measures, referred to as the
“primary end points,” is crucial. The most controversial
aspect of this choice often relates to the reliability of using
surrogate end points as true measures of clinical efficacy.
However, the use of biological markers in the progression of
HF has important potential. Use of such markers as surro-
gate end points allows all patients in the trial to contribute
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to the study end point, resulting in smaller sample size,
shorter trial duration and reduced cost. Patients with even
mild disease could be studied, and preventive strategies
could therefore be evaluated. Moreover, surrogate end
points could allow investigators to make more rapid evalu-
ations of promising interventions than could be made using
primary end points. More importantly, surrogate end points
can aid our understanding of the biologic processes under-
lying the disease and the mechanisms of therapy. Neverthe-
less, the reliability of efficacy assessments based on surrogate
end points can be seriously challenged, and we should be
suspicious of calculated sample sizes that appear too small or
follow-up periods that appear too short. The issue, there-
fore, is not so much the sample sizes for the surrogate
points, but whether one really is ready to accept the
surrogate as being adequately important.
At present, the one perfect surrogate marker for mortality
and QOL in assessing patients with HF remains elusive.
Chronic HF is a complex syndrome; to expect any single
parameter to be universally predictive of drug effects on
mortality and QOL may be too simplistic. A composite of
surrogate end points may be more appropriate than any
single one. The most promising surrogate end points seem
to be exercise capacity assessed by oxygen consumption,
plasma natriuretic peptides, and measurements of LV di-
mensions and EF. It is therefore important to carry out
mortality trials with surrogate markers incorporated into the
study. The Valsartan Heart Failure Trial (Val-HeFT), for
example, evaluated the effect of valsartan on HF morbidity
and mortality and measured several biological markers, such
as LV dimensions, EF, neurohormones and QOL in all
patients, and Holter monitoring, exercise tolerance and
cardiac remodeling assessed by magnetic resonance imaging
in a subset of patients (11,82). The results of some of these
substudies and similarly designed trials in the future should
help establish the validity of these markers as surrogates for
clinical events.
In this review we have mentioned some statistical meth-
ods useful in the evaluation of potential surrogates, but both
the biological knowledge and the understanding are para-
mount, and no amount of statistical methodology can
ensure the appropriateness of a putative surrogate, although
it may rule out candidates that do not perform well.
The availability of the newer drugs for HF makes it even
more important to have valid surrogate end points. As more
and more drugs are added to the current standard regimen,
a time will come when physicians will have to consider
withdrawing or replacing one of the standard drugs, because
not all drugs have similar beneficial effects on all patients. At
present there is no way of knowing whether an agent is
having a beneficial effect on a particular patient. Availability
of valid surrogate end points would help solve the ethical
dilemma concerning withdrawing a standard drug in a
patient who is still symptomatic on that drug. A less
significant p value for the difference in a true end point may
be adequate for therapeutic approval when robust favorable
data on established surrogate markers are available to
support the result.
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